AOD-9604

AOD-9604 is a modified fragment of the C-terminus of human growth hormone (hGH), corresponding to amino acids 177-191 with a tyrosine residue modification. It has been studied in laboratory settings for its activity in lipolysis and lipid metabolism pathways, independent of IGF-1 signaling.

AOD-9604 is a synthetic peptide fragment derived from the C-terminal region (amino acids 177-191) of human growth hormone. It is investigated in research for its lipolytic properties and its ability to modulate lipid metabolism independently of growth-promoting signaling cascades. Supplied as a lyophilized research peptide.

AOD-9604 was originally developed and characterized by researchers at Monash University in Australia during the 1990s. The peptide was designed as a truncated analogue of hGH to isolate lipolytic activity from somatotropic signaling. It has been the subject of multiple published preclinical studies examining its metabolic profile.

Preclinical research has shown that AOD-9604 stimulates lipolysis and inhibits lipogenesis in adipose tissue models without affecting IGF-1 levels or glucose homeostasis. Animal studies have reported changes in body composition parameters following administration. Its mechanism of action is believed to involve beta-3 adrenergic receptor pathways.